Nuveen, LLC Candel Therapeutics, Inc. Transaction History
Nuveen, LLC
- $363 Billion
- Q3 2025
A detailed history of Nuveen, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 209,662 shares of CADL stock, worth $966,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
209,662
Previous 92,482
126.71%
Holding current value
$966,541
Previous $467,000
130.62%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CADL
# of Institutions
87Shares Held
14.9MCall Options Held
313KPut Options Held
127K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$11.9 Million6.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$9.25 Million0.0% of portfolio
-
Northpond Ventures, LLC1.94MShares$8.92 Million48.35% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.38MShares$6.38 Million0.45% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$4.28 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $133M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...